U.K. gatekeepers doubt the value of Millennium Crohn's med

The U.K.'s cost-effectiveness watchdog says it's not planning to recommend a new Crohn's disease treatment from Millennium Pharmaceuticals. The National Institute for Health and Care Excellence (NICE) cited uncertain evidence for the drug, Entyvio, and said it's unlikely it would be a good value for the National Health Service. The draft decision comes despite the Takeda unit's offer of a discount. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.